| Literature DB >> 10579814 |
A L Hopkins1, J Ren, H Tanaka, M Baba, M Okamato, D I Stuart, D K Stammers.
Abstract
Two analogues of the nonnucleoside inhibitor of HIV-1 RT, MKC-442 (emivirine), containing different C6 substituents have been designed to be less susceptible to the commonly found drug-resistance mutation of Tyr181Cys. Compound TNK-6123 had a C6 thiocyclohexyl group designed to have more flexibility in adapting to the mutated drug-binding site. GCA-186 had additional 3',5'-dimethyl substituents aimed at forming close contacts with the conserved residue Trp229. Both compounds showed approximately 30-fold greater inhibitory effect than MKC-442 to the Tyr181Cys mutant virus as well as to the clinically important Lys103Asn virus. X-ray crystallographic structure determination of complexes with HIV-1 RT confirmed the predicted binding modes. These strategies might be used to improve the resilience of other NNRTI series against common drug-resistance mutations.Entities:
Mesh：
Substances：
Year: 1999 PMID： 10579814 DOI： 10.1021/jm990192c
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446